Literature DB >> 19204184

Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling.

Jun Cai1, Fang-Fang Yi, Long Yang, Di-Fei Shen, Qinling Yang, Ankang Li, Asish K Ghosh, Zhou-Yan Bian, Ling Yan, Qi-Zhu Tang, Hongliang Li, Xin-Chun Yang.   

Abstract

Receptor-associated late transducer (RALT) is a feedback inhibitor of epidermal growth factor receptor signaling. RALT has been shown previously to be induced in the ischemic heart and to promote cardiomyocyte apoptosis in vitro. However, the role of RALT in cardiac hypertrophy remains unclear. We hypothesized that forced expression of RALT in the murine heart would protect the heart against cardiac hypertrophy in vivo. We investigated the effect of cardiac overexpression of rat RALT on cardiac hypertrophy induced by angiotensin II and isoproterenol in RALT transgenic mice and wild-type littermates. The extent of cardiac hypertrophy was assessed by 2D and M-mode echocardiography as well as by molecular and pathological analyses of cardiac samples. Constitutive expression of rat RALT in cardiac myocytes of murine heart attenuated both hypertrophic and inflammatory responses and preserved cardiac function. These beneficial effects were associated with the attenuation of the epidermal growth factor receptor-dependent cascade that was triggered by angiotensin II and isoproterenol stimulation. Additional evidence demonstrated that RALT expression blocked fibrosis in vivo and collagen synthesis in vitro. Therefore, cardiac overexpression of RALT improves cardiac function and inhibits maladaptive hypertrophy, inflammation, and fibrosis through attenuating epidermal growth factor receptor-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204184      PMCID: PMC2845399          DOI: 10.1161/HYPERTENSIONAHA.108.120816

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

Review 1.  Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease.

Authors:  Jonathan A Epstein; Michael S Parmacek
Journal:  Circulation       Date:  2005-07-26       Impact factor: 29.690

Review 2.  The fuzzy logic of physiological cardiac hypertrophy.

Authors:  Gerald W Dorn
Journal:  Hypertension       Date:  2007-03-26       Impact factor: 10.190

Review 3.  Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look.

Authors:  Timothy L Reudelhuber; Kenneth E Bernstein; Patrick Delafontaine
Journal:  Hypertension       Date:  2007-04-23       Impact factor: 10.190

Review 4.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.

Authors:  Puja K Mehta; Kathy K Griendling
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-26       Impact factor: 4.249

5.  Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.

Authors:  Hong-Liang Li; Ming-Lei Zhuo; Dong Wang; Ai-Bing Wang; Hua Cai; Li-Hong Sun; Qinglin Yang; Yue Huang; Yu-Sheng Wei; Peter P Liu; De-Pei Liu; Chih-Chuan Liang
Journal:  Circulation       Date:  2007-03-26       Impact factor: 29.690

6.  An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.

Authors:  Peiyong Zhai; Jonathan Galeotti; Jing Liu; Eric Holle; Xianzhong Yu; Thomas Wagner; Junichi Sadoshima
Journal:  Circ Res       Date:  2006-08-10       Impact factor: 17.367

7.  EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.

Authors:  William D Hardie; Cynthia Davidson; Machiko Ikegami; George D Leikauf; Timothy D Le Cras; Adrienne Prestridge; Jeffrey A Whitsett; Thomas R Korfhagen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-18       Impact factor: 5.464

Review 8.  A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy.

Authors:  Bukhtiar H Shah; Kevin J Catt
Journal:  Trends Pharmacol Sci       Date:  2003-05       Impact factor: 14.819

9.  Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice.

Authors:  Hong-Liang Li; Zhi-Gang She; Tian-Bo Li; Ai-Bing Wang; Qinglin Yang; Yu-Sheng Wei; Yi-Guang Wang; De-Pei Liu
Journal:  Hypertension       Date:  2007-04-09       Impact factor: 10.190

10.  Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins.

Authors:  Hui-Hua Li; Monte S Willis; Pamela Lockyer; Nathaniel Miller; Holly McDonough; David J Glass; Cam Patterson
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

View more
  13 in total

1.  Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1-Smad signalling.

Authors:  Ling Yan; Xiang Wei; Qi-Zhu Tang; Jinghua Feng; Yan Zhang; Chen Liu; Zhou-Yan Bian; Lian-Feng Zhang; Manyin Chen; Xue Bai; Ai-Bing Wang; John Fassett; Yingjie Chen; You-Wen He; Qinglin Yang; Peter P Liu; Hongliang Li
Journal:  Cardiovasc Res       Date:  2011-06-01       Impact factor: 10.787

2.  Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.

Authors:  He Huang; Qi-Zhu Tang; Ai-Bing Wang; Manyin Chen; Ling Yan; Chen Liu; Hong Jiang; Qinglin Yang; Zhou-Yan Bian; Xue Bai; Li-Hua Zhu; Lang Wang; Hongliang Li
Journal:  Hypertension       Date:  2010-06-28       Impact factor: 10.190

3.  Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload.

Authors:  Hongliang Li; Chengwei He; Jinhua Feng; Yan Zhang; Qizhu Tang; Zhouyan Bian; Xue Bai; Heng Zhou; Hong Jiang; Scott P Heximer; Mu Qin; He Huang; Peter P Liu; Congxin Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

4.  Nuclear Gene 33/Mig6 regulates the DNA damage response through an ATM serine/threonine kinase-dependent mechanism.

Authors:  Cen Li; Soyoung Park; Xiaowen Zhang; Leonard M Eisenberg; Hong Zhao; Zbigniew Darzynkiewicz; Dazhong Xu
Journal:  J Biol Chem       Date:  2017-08-25       Impact factor: 5.157

5.  New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.

Authors:  Mazen Kurdi; George W Booz
Journal:  Hypertension       Date:  2011-04-18       Impact factor: 10.190

Review 6.  Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.

Authors:  Laurel A Grisanti; Shuchi Guo; Douglas G Tilley
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

7.  A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation.

Authors:  Yuri Frosi; Sergio Anastasi; Costanza Ballarò; Giulia Varsano; Loriana Castellani; Elena Maspero; Simona Polo; Stefano Alemà; Oreste Segatto
Journal:  J Cell Biol       Date:  2010-04-26       Impact factor: 10.539

8.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

9.  Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling.

Authors:  Di-Fei Shen; Qi-Zhu Tang; Ling Yan; Yan Zhang; Li-Hua Zhu; Lang Wang; Chen Liu; Zhou-Yan Bian; Hongliang Li
Journal:  Br J Pharmacol       Date:  2010-01-25       Impact factor: 8.739

10.  Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension.

Authors:  Jia Liu; Jiamei Liu; Linying Shi; Fan Zhang; Liping Yu; Xinchun Yang; Jun Cai
Journal:  Int J Mol Med       Date:  2018-01-23       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.